Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 24, 2015 6:06 PM ET

Pharmaceuticals

Company Overview of Bluefish Pharmaceuticals AB

Company Overview

Bluefish Pharmaceuticals AB, together with its subsidiaries, develops, manufactures, and markets generic pharmaceuticals in Sweden and internationally. It provides a portfolio of generic pharmaceuticals in various therapeutic areas, such as cardiovascular, central nervous system, gastrointestinal, diabetes, oncology, dermatology, respiratory, inflammatory, genito-urinary, antifungal, antiviral, endocrinology, analgesic, and antibiotics. The company sells its products through a network of independent wholesalers and pharmacies. Bluefish Pharmaceuticals AB was founded in 2005 and is headquartered in Stockholm, Sweden.

Torsgatan 11

Stockholm,  111 23

Sweden

Founded in 2005

90 Employees

Phone:

46 8 51 91 16 00

Fax:

46 8 51 91 16 90

Key Executives for Bluefish Pharmaceuticals AB

Founder, Chief Executive Officer, President, Managing Director, Member of the Management Group and Director
Age: 40
Chief Financial Officer and Member of the Management Group
Age: 43
Member of the Management Group and Chief Executive Officer of Bluefish Global Technology Center
Age: 55
Head of development and Quality Assurance
Director of Bluefish India office
Compensation as of Fiscal Year 2014.

Bluefish Pharmaceuticals AB Key Developments

Bluefish Pharmaceuticals Announces Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for the Fiscal 2015

Bluefish Pharmaceuticals announced earnings results for the first quarter of 2015. Net sales were SEK 70.8 million against SEK 44.5 million a year ago. EBITDA for the period, adjusted for currency effects, was SEK 2.8 million against loss of SEK 10.0 million a year ago. Basic loss per share amounted to SEK 0.06 against SEK 0.24 a year ago. Growth in net sales during the first quarter is, for the most part, due to the launch of existing products in new markets, primarily Spain, along with higher market share in established markets such as Sweden. The company has resulted in positive EBITDA of SEK 3.7 million for the period. For the year 2015, net sales will fluctuate from quarter to quarter. However, the company expects net sales for the full year 2015 to increase compared to 2014. Growth originates from prior contracts, planned product launches and an overall increase in market share. Additionally, gross margin is expected to surpass last year's level.

Bluefish Pharmaceuticals AB Provides Earnings Guidance for the Year 2015

Bluefish Pharmaceuticals AB provided earnings guidance for the year 2015. For the year, The company expects that net sales in 2015 will grow. The increase will come from already secured tenders, planned new product launches as well as a general increase in market share. The expansion in gross margin is expected to continue, however, not in parity with that of the fourth quarter of 2014. With an expected increase in revenues, together with an expansion of the gross margin, The company anticipates a positive EBITDA in 2015.

Bluefish Pharmaceuticals AB Reports Consolidated and Parent Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Bluefish Pharmaceuticals AB reported consolidated and parent earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, on consolidated basis, the company reported net sales of SEK 60,271,000 compared to SEK 43,649,000 a year ago. Operating loss was SEK 6,444,000 compared to SEK 22,479,000 a year ago. Loss after financial items was SEK 7,569,000 compared to SEK 24,179,000 a year ago. Loss was SEK 7,569,000 or SEK 0.35 per share before and after dilution compared to SEK 24,701,000 or SEK 0.53 per share before and after dilution a year ago. LBITDA was SEK 1,446,000 compared to SEK 14,348,000 a year ago. Cash flow from operating activities was SEK 8,994,000 compared to SEK 13,270,000 a year ago. For the year, on consolidated basis, the company reported net sales of SEK 187,748,000 compared to SEK 175,505,000 a year ago. Operating loss was SEK 56,102,000 compared to SEK 49,803,000 a year ago. Loss after financial items was SEK 61,377,000 compared to SEK 57,585,000 a year ago. Loss was SEK 62,519,000 or SEK 0.82 per share before and after dilution compared to SEK 58,494,000 or SEK 0.90 per share before and after dilution last year. LBITDA was SEK 34,109,000 compared to SEK 31,401,000 last year. Cash flow used in operating activities was SEK 25,632,000 compared to cash used in operating activities of SEK 29,363,000 a year ago. For the quarter, on parent basis, the company reported net sales of SEK 57,259,000 compared to SEK 42,125,000 a year ago. Operating loss was SEK 7,447,000 compared to SEK 23,157,000 a year ago. Net loss was SEK 8,776,000 compared to SEK 26,230,000 a year ago. For the year, on parent basis, the company reported net sales of SEK 185,148,000 compared to SEK 172,521,000 a year ago. Operating loss was SEK 54,217,000 compared to SEK 49,516,000 a year ago. Net loss was SEK 61,951,000 compared to SEK 58,707,000 last year.

Similar Private Companies By Industry

Company Name Region
Imed AB Europe
GliGene AB Europe
CMC Contrast AB Europe
Synartro AB Europe
Glactone Pharma AB Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bluefish Pharmaceuticals AB, please visit www.bluefishpharma.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.